Sparsentan: First Approval

Sparsentan (FILSPARI™) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS). In February 2023, sparsentan received accelerated approval in the...

Descripción completa

Detalles Bibliográficos
Autor principal: Syed, Yahiya Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232600/
https://www.ncbi.nlm.nih.gov/pubmed/37022667
http://dx.doi.org/10.1007/s40265-023-01864-x
_version_ 1785052018169085952
author Syed, Yahiya Y.
author_facet Syed, Yahiya Y.
author_sort Syed, Yahiya Y.
collection PubMed
description Sparsentan (FILSPARI™) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS). In February 2023, sparsentan received accelerated approval in the USA for reducing proteinuria in adults with primary IgA nephropathy who are at risk of rapid disease progression. This article summarizes the milestones in the development of sparsentan leading to this first approval for IgA nephropathy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-023-01864-x.
format Online
Article
Text
id pubmed-10232600
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-102326002023-06-02 Sparsentan: First Approval Syed, Yahiya Y. Drugs AdisInsight Report Sparsentan (FILSPARI™) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS). In February 2023, sparsentan received accelerated approval in the USA for reducing proteinuria in adults with primary IgA nephropathy who are at risk of rapid disease progression. This article summarizes the milestones in the development of sparsentan leading to this first approval for IgA nephropathy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-023-01864-x. Springer International Publishing 2023-04-06 2023 /pmc/articles/PMC10232600/ /pubmed/37022667 http://dx.doi.org/10.1007/s40265-023-01864-x Text en © Springer Nature 2023, corrected publication 2023 https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle AdisInsight Report
Syed, Yahiya Y.
Sparsentan: First Approval
title Sparsentan: First Approval
title_full Sparsentan: First Approval
title_fullStr Sparsentan: First Approval
title_full_unstemmed Sparsentan: First Approval
title_short Sparsentan: First Approval
title_sort sparsentan: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232600/
https://www.ncbi.nlm.nih.gov/pubmed/37022667
http://dx.doi.org/10.1007/s40265-023-01864-x
work_keys_str_mv AT syedyahiyay sparsentanfirstapproval

Ejemplares similares